Please login to the form below

Vimpat

This page shows the latest Vimpat news and features for those working in and with pharma, biotech and healthcare.

Tecentriq’s triple negative breast cancer use among key CHMP nods

UCB’s Vimpat (lacosamide) also gained a thumbs up in the epilepsy market, with a recommendation in partial-onset seizures with or without secondary generalisation. ... This most recent indication sees Vimpat continue on its trajectory to blockbuster

Latest news

UCB looks to pipeline with five years left for twin blockbusters

CEO outlines pipeline promise, won't write off post-Brexit UK. Mid-sized pharma company UCB has seen its epilepsy treatment Vimpat break through the $1bn+ annual revenues mark, joining its ... Vimpat is forecast to reach 1.4bn by 2022, the year its US
UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Vimpat added another 495m.
UCB wins European approval for epilepsy drug Briviact

The drug adds to an epilepsy treatment portfolio at UCB currently represented by Vimpat (lacosamide) - with sales of 495m in the first nine months of 2015 - along with Keppra (levetiracetam) which
UCB boosted by core medicines growth

Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Sales of Vimpat increased by 15%
UCB submits brivaracetam for use in epilepsy

The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). ... At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.

More from news
Approximately 7 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.
VIDEO interview: Neil Weir, UCB

For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for ... As for the future of the company,
Interview with Roch Doliveux, UCB

It is the same with Vimpat. Peak sales were once 350m; now, estimates are at least 1.2bn. ... Vimpat treats a subset of epilepsy, partial onset seizures. One in three patients has this refractory type of seizure.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...